Kornitzer Capital Management Inc. KS Acquires 312,115 Shares of ADMA Biologics Inc $ADMA

Kornitzer Capital Management Inc. KS boosted its holdings in ADMA Biologics Inc (NASDAQ:ADMA) by 652.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 359,985 shares of the biotechnology company’s stock after purchasing an additional 312,115 shares during the period. Kornitzer Capital Management Inc. KS owned about 0.15% of ADMA Biologics worth $5,277,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. State Street Corp boosted its holdings in shares of ADMA Biologics by 5.6% in the 2nd quarter. State Street Corp now owns 12,078,505 shares of the biotechnology company’s stock worth $219,950,000 after buying an additional 637,727 shares during the last quarter. Geode Capital Management LLC raised its position in ADMA Biologics by 4.3% in the second quarter. Geode Capital Management LLC now owns 5,913,121 shares of the biotechnology company’s stock worth $107,691,000 after acquiring an additional 245,309 shares during the period. American Century Companies Inc. boosted its stake in ADMA Biologics by 8.4% in the second quarter. American Century Companies Inc. now owns 4,610,989 shares of the biotechnology company’s stock valued at $83,966,000 after acquiring an additional 358,627 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in ADMA Biologics by 8.9% in the second quarter. Allspring Global Investments Holdings LLC now owns 3,320,251 shares of the biotechnology company’s stock valued at $59,366,000 after acquiring an additional 271,305 shares during the last quarter. Finally, Thrivent Financial for Lutherans grew its position in shares of ADMA Biologics by 78.1% during the 2nd quarter. Thrivent Financial for Lutherans now owns 3,315,425 shares of the biotechnology company’s stock valued at $60,373,000 after acquiring an additional 1,453,924 shares during the period. 75.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $28.50.

ADMA Biologics Price Performance

Shares of NASDAQ:ADMA opened at $16.58 on Wednesday. The company has a quick ratio of 3.65, a current ratio of 7.13 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $3.95 billion, a PE ratio of 19.28 and a beta of 0.47. ADMA Biologics Inc has a twelve month low of $13.50 and a twelve month high of $25.67. The company has a 50-day moving average price of $18.55 and a two-hundred day moving average price of $17.06.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.16. The company had revenue of $134.22 million for the quarter, compared to analyst estimates of $131.20 million. ADMA Biologics had a net margin of 42.87% and a return on equity of 36.52%. The company’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.15 earnings per share. Equities analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.